The cure rate from use of Sensus Healthcare’s SRT-100 for treating basal and squamous cell carcinomas of the lower extremities among older patients (mean age: 82.5 years) exceeds 97%, according to a retrospective study published in the Journal of Drugs in Dermatology.
“When treating NMSC of the lower extremities, it is critically important to examine every treatment option that doesn’t inflict more pain or add potential complications as many of these patients are elderly and present with numerous comorbidities,” says William Roth, MD, the lead author of the study and Voluntary Clinical Professor at The University of Miami School of Medicine, Department of Dermatology.
“The results of this study highlight SRT as a highly effective treatment option for eliminating basal and squamous cell carcinoma lesions on lower extremities.”
SRT effectively treats basal and squamous cell carcinomas without cutting, bleeding, or stitching. There is no need for anesthesia and no need for reconstructive plastic surgery. Sensus’ SRT-100 is cleared by the US Food and Drug Administration for the treatment of non-melanoma skin cancer and keloids, according to a news release from Sensus Healthcare.
“The power of this technology lies in our ability to deliver a precise, calibrated dose of X-ray radiation that penetrates only five millimeters below the skin’s surface,” added Isabelle Raymond, PhD, Vice President, Clinical Development, Sensus Healthcare.
“Dr Roth’s study demonstrates that basal cell carcinoma and squamous cell carcinoma of the lower extremities can be treated safely and very successfully with superficial radiation therapy, and that it is a viable nonsurgical treatment option for patients who do not want surgery.”
[Source(s): Sensus Healthcare, PR Newswire]
